Akèy › Kansè tete negatif triple › New Mexico
Etid klinik pou Kansè tete negatif triple nan New Mexico
3 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan New Mexico.
Vil nan New Mexico
Tèks ofisyèl etid la (Anglè)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0090), Albuquerque
- CHRISTUS St. Vincent Regional Cancer Center ( Site 0118), Santa Fe
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University of New Mexico, Albuquerque
- San Juan Oncology Associates, Farmington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.